J4 ›› 2012, Vol. 38 ›› Issue (2): 225-229.

• 基础研究 • 上一篇    下一篇

GST与FGF23 C末端 71个氨基酸融合蛋白的表达、纯化及其免疫原性

陈玉斌1,2|刘孝菊1,3,4|姚娜1|孙常文1,2|田海山1.4|张键1,2|刘敏1,2|李校堃1,2,3,4   

  1. (1.吉林农业大学 生物反应器与药物开发教育部工程研究中心,吉林 长春 |130118;2.吉林农业大学 生命科学学院,吉林 长春 130118;3.吉林大学公共卫生学院 卫生部放射生物学重点实验室,吉林 长春 130021;4.温州医学院药学院 生物技术制药工程重点实验室|浙江 温州 325035)
  • 收稿日期:2011-10-25 出版日期:2012-03-28 发布日期:2012-03-28
  • 通讯作者: 李校堃 E-mail:(Tel:0431-84533348,E-mail:xiaokunli@163.com)
  • 作者简介:陈玉斌(1985-)|男|河北省邯郸市人|农学硕士|主要从事生物反应器与生物制药的研究。
  • 基金资助:

    国家863计划资助课题(2011AA02A113);浙江省温州市第4期科技项目资助课题(Y20100181);浙江省温州市科技局项目资助课题(Y20100184)

Expression and purification of GST and FGF23 C termination fusion protein and its immunogenicity

CHEN Yu-bin1,2,LIU Xiao-ju1,3,4,YAO Na1,SHUN Chang-wen1,2,TIAN Hai-shan1,4,ZHANG Jian1,2|LIU Min1,2|LI Xiao-kun1,2,3,4   

  1. (1.Engineering Research Center of Bioreactor and Pharmaceutical Development, Ministry of Education, Jilin Agricultural University, |Changchun |130118, China;2.School of Life Science, Jilin Agricultural University, Changchun |130118, China;3. Key Laboratory of Radiobiology,Ministry of Health,School of Public Health, Jilin University, Changchun |130021, China;4. Key Laboratory of Biotechnology Pharmaceutical Engineering,School of Pharmacy,Wenzhou Medical College, Wenzhou |325035,China)
  • Received:2011-10-25 Online:2012-03-28 Published:2012-03-28

摘要:

目的:构建和表达谷胱甘肽-S-转移酶(GST)与成纤维细胞生长因子23(FGF-23)的活性片段-C末端71个氨基酸(FGF23CTR)融合蛋白的基因工程菌,并检测融合蛋白的免疫原性,为制备FGF23特异性单克隆抗体以及研发慢性肾病诊断试剂提供实验数据。方法:以质粒pET22b-fgf23为模板利用PCR方法扩增FGF23CTR的基因片段,将该基因与表达载体pGEX-4T-1连接后转化至BL21宿主细胞中,通过IPTG诱导获得可溶性表达,将GST-FGF23CTR融合蛋白用Glutathione Sepharose4B亲和层析法纯化,Western blotting法鉴定蛋白。该融合蛋白免疫Balb/C小鼠制备抗血清,采用ELISA法检测抗血清的效价。结果:构建GST-FGF23CTR融合蛋白的表达载体,纯化后得到纯度90%以上的融合蛋白,并与商品化的FGF23多克隆抗体呈阳性反应,ELISA法证实融合蛋白具有良好的免疫原性。结论:成功构建GST-FGF23CTR融合蛋白基因工程菌,并纯化得到具有良好免疫原性的融合蛋白,以此方法制备的抗原可用于FGF23特异性单克隆抗体的制备和FGF23生物学功能研究。

关键词: 成纤维细胞生长因子23;免疫原性;基因工程菌

Abstract:

To construct the genetic engineering bacteria highly expressing fusion protein of glutathione-S-transferase ( GST ) and C-terminal 71 amino acids of fibroblast growth factor 23 ( FGF23CTR ),and to test the immunogenicity of the fusion protein and  to provide experimental data for FGF23 specific monoclonal antibodies and the development of diagnosis reagent for  chronic kidney disease.Methods After FGF23CTR gene fragment was obtained by PCR,it was fused with GST by expression vector pGEX-4T-1,then was transformed in E.coli BL21(DE3). By inducing with 1IPTG,the fusion proteins were expressed solubly.The fused protein was purified by Glutathione Sepharose4B.The purity of GST-FGF23CTR by SDS-PAGE was shown to be higher than 90%.The   Balb/C mice  were immuned   with fusion protein to pepare antiserum,then  ELISA was used to assay antiserum titer.Results The GST-FGF23CTR expression vector was constructed successfully.The purity of fusion protein was more than 90% after purification,and it positively reacted  to the commercialization of FGF23 polyclonal antibody.The ELISA result showed that the confirmed fusion protein had  good immunogenicity.Conclusion The genetic engineering bacteria of GST-FGF23CTR is successfully constructed and the purified protein has good immunogenicity.The fused protein can be used for the FGF23 monoclonal antibody preparation and research on the biological function of FGF23.

Key words: fibroblast growth factor 23;immunogenicity;genetic engineering bacteria

中图分类号: 

  •